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Abstract
Background: Given the significant impact on public health and drug development, drug safety has been a focal
point and research emphasis across multiple disciplines in addition to scientific investigation, including consumer
advocates, drug developers and regulators. Such a concern and effort has led numerous databases with drug
safety information available in the public domain and the majority of them contain substantial textual data. Text
mining offers an opportunity to leverage the hidden knowledge within these textual data for the enhanced
understanding of drug safety and thus improving public health.
Methods: In this proof-of-concept study, topic modeling, an unsupervised text mining approach, was performed
on the LiverTox database developed by National Institutes of Health (NIH). The LiverTox structured one document
per drug that contains multiple sections summarizing clinical information on drug-induced liver injury (DILI). We
hypothesized that these documents might contain specific textual patterns that could be used to address key DILI
issues. We placed the study on drug-induced acute liver failure (ALF) which was a severe form of DILI with limited
treatment options.
Results: After topic modeling of the “Hepatotoxicity” sections of the LiverTox across 478 drug documents, we
identified a hidden topic relevant to Hy’s law that was a widely-accepted rule incriminating drugs with high risk of
causing ALF in humans. Using this topic, a total of 127 drugs were further implicated, 77 of which had clear ALF
relevant terms in the “Outcome and management” sections of the LiverTox. For the rest of 50 drugs, evidence
supporting risk of ALF was found for 42 drugs from other public databases.
Conclusion: In this case study, the knowledge buried in the textual data was extracted for identification of drugs
with potential of causing ALF by applying topic modeling to the LiverTox database. The knowledge further guided
identification of drugs with the similar potential and most of them could be verified and confirmed. This study
highlights the utility of topic modeling to leverage information within textual drug safety databases, which
provides new opportunities in the big data era to assess drug safety.
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Background
In recent years, numerous drug safety databases have
been made publicly available, e.g., LiverTox http://liver-
tox.nlm.nih.gov/ [1], SIDER http://sideeffects.embl.de/
[2], TOXNET http://toxnet.nlm.nih.gov/, the US Food
and Drug Administration (FDA) Adverse Event Report-
ing System (FAERS), and PubMed http://www.ncbi.nlm.
nih.gov/pubmed. These databases contribute signifi-
cantly to the research community, facilitating the
enhanced understanding of drug safety issues [3].
Mining large-scale drug safety data is a promising venue
for drug regulation [4]. Some databases integrated the
safety data from various sources with free text format,
for which text mining would be effective to leverage the
textual information to gain knowledge of drug safety,
and thus address critical safety issues that are difficult
to be approached by using other databases.
Topic modeling is a widely used text mining approach
for analysis of large volumes of unlabeled documents in
order to discover hidden textual patterns [5]. Previous
studies in our group demonstrated that topic modeling
could be effectively used for the analysis of adverse
events for drug safety assessment from the FDA-
approved drug labels [6], and for the identification of
opportunities for drug repositioning [7]. The National
Institutes of Health (NIH) LiverTox database provides
comprehensive clinical information for drug-induced
liver injury (DILI) which is summarized with a free-text
format in several sections.
In this study, we extended our text mining effort with
topic modeling to the LiverTox database to ask the
question of whether additional knowledge beyond what
had been described in the documents could be extracted
to guide an enhanced DILI assessment. We placed our
emphasis on drug-induced acute liver failure (ALF)
which was a severe form of DILI with limited treatment
options thus with significant public health impact. With
topic modeling, we successfully identified a topic incri-
minating a drug’s liability to cause ALF based on the
text in the “Hepatotoxicity” sections of the LiverTox.
The identified topic further guided identification of
other drugs with the similar liability and, importantly,
most of them could be verified and confirmed with
additional data. This proof-of-concept study demon-
strated the potential utility of topic modeling to the
existing text documents in the public domain to gain
knowledge as predictive means for the enhanced assess-
ment of drug safety.
Methods
LiverTox database
The NIH LiverTox database is developed by Liver Disease
Research Branch of National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK) and National
Library of Medicine (NLM) to promote the basic and clin-
ical research on DILI [1]. It is a free on-line source of tex-
tual documents on DILI summarized from various
databases, scientific literature, and interpretations of the
curators. The LiverTox contains a set of documents (one
document per drug) and each document contains multiple
sections. Each section provides different set of DILI infor-
mation, including introduction, background, hepatotoxi-
city, mechanism of injury, outcome and management, and
others (e.g., case report, product information, chemical
structure, and references). In this study, only the “Hepato-
toxicity” section was used for topic modeling because the
“Hepatotoxicity” section mainly contained the DILI-rele-
vant clinical observations. The findings was compared
against to the information from other sections such as
“Outcome and management” to demonstrate the utility of
the method. In case of no clear ALF evidence presented in
those sections, the results were compared to the data from
other sources. The “Hepatotoxicity” section for each drug,
on average, contains 200-400 words that summarize the
DILI-relevant information including clinical features, time
to onset and recovery, liver enzymes (frequency of eleva-
tion, fold change, and serum levels), liver injury pattern,
immunoallergic and autoimmune features, and other
hepatotoxicity relevant data. A total of 478 documents
(i.e., 478 drugs) were used for topic modeling.
Topic modeling
Latent Dirichlet allocation (LDA), one of the most pop-
ular topic modeling approach [5,8-10], was applied to
explore the LiverTox database. We used LDA in Mallet,
a Java-based package, for topic modeling [11]. Number
of topics to optimally represent the content of all docu-
ments is a key parameter in a topic model. The optimal
number of topics can be determined by fitting models
with different number of topics to the data. The model
fitness can be estimated by the likelihood of the data
given a topic model [10]. To obtain the sparse topic and
word distributions, the Dirichlet hyperparameters alpha
(a) and beta (b) were defined as 0.1 and 0.01, respec-
tively. Before topic modeling, the English stop-words
and numerical digits are removed. In addition, three
words (i.e., liver, injury, and elevation) presented in
more than 80% of documents are also removed as the
words with high frequency across the documents will
not provide the discriminative information for topics.
After that, words in each document are tokenized and
then put into LDA to train a topic model. The model
yields two probability distributions, one gives a probabil-
ity value (θ) for each topic to determine its relevance to
each document and the other assigns a probability value
to each word for its relevance to the topic.
Yu et al. BMC Bioinformatics 2014, 15(Suppl 17):S6
http://www.biomedcentral.com/1471-2105/15/S17/S6
Page 2 of 8
Identification of ALF-Topic
As listed in Table 1, 26 drugs known to cause ALF are
selected and used to identify a topic most relevant to
ALF in the topic model. There are 23 drugs annotated
by Suzuki et al. with a justified causality assessment
from the ALF survey conducted in the United States
[12]. Another 3 drugs (i.e., benzbromarone, tolcapone,
and troglitazone) are withdrawn from the market due to
the drug-induced ALF.
For the 26 known ALF drugs, a mean topic distribu-
tion of these drugs is calculated, which leads to the
determination of a topic that represents best for these
ALF drugs. This so-called ALF-Topic is defined to be
topic j for which the mean probability value of θj is the
greatest among all the topics. In this model, other drugs
highly associated with ALF-Topic are expected to be
related to ALF.
Investigation of drugs implicated by ALF-Topic
To investigate whether there was any evidence to sup-
port the ALF-implicated drugs identified by ALF-Topic,
we searched the ALF evidence in their “Outcome and
management” sections from the LiverTox database, in
the safety sections from the FDA-approved drug labels,
in the literature reporting the ALF case reports with the
established causality, and in the FAERS with post-mar-
keting ALF case reports from 1969 to 2013. The work-
flow of this study is depicted in Figure 1.
Results
Identification of ALF-Topic
The study started with the determination of the optimal
number of topics for the LiverTox dataset. Consequently,
40 topics were determined as the highest likelihood of
the data given the model with the varying number of
Table 1 Summary of topic model for the 26 known ALF drugs in LiverTox database
Known ALF drugs 1st topic 2nd topic 3rd topic 4th topic
Topic ID Prob. Topic ID Prob. Topic ID Prob. Topic ID Prob.
Acetaminophen 37 4.7E-01 29 3.6E-01 4 1.4E-01 6 1.6E-02
Amoxicillin/clavulanate 37 6.3E-01 4 1.9E-01 15 1.2E-01 20 6.1E-02
Atorvastatin 31 8.3E-01 39 1.7E-01 40 3.3E-05 38 3.3E-05
Benzbromarone* 28 4.4E-01 37 4.2E-01 11 1.4E-01 40 3.8E-05
Carbamazepine 3 4.6E-01 35 3.5E-01 38 1.9E-01 40 6.7E-05
Ciprofloxacin 15 7.7E-01 14 2.3E-01 40 2.8E-05 39 2.8E-05
Cyclophosphamide 31 6.4E-01 19 2.9E-01 40 6.2E-02 39 5.2E-05
Dapsone 7 8.0E-01 31 2.0E-01 40 3.3E-05 39 3.3E-05
Diclofenac 37 8.0E-01 20 1.4E-01 23 3.3E-02 22 2.2E-02
Disulfiram 37 3.6E-01 38 2.6E-01 28 2.2E-01 7 1.6E-01
Doxycycline 37 5.9E-01 17 3.3E-01 22 7.2E-02 40 3.6E-05
Ethambutol 28 3.9E-01 10 3.5E-01 7 1.7E-01 24 8.7E-02
Halothane 23 7.1E-01 37 2.8E-01 16 6.5E-03 40 1.6E-05
Ibuprofen 31 3.2E-01 21 2.9E-01 37 2.0E-01 16 1.3E-01
Isoniazid 37 6.2E-01 23 1.2E-01 10 9.5E-02 16 6.7E-02
Methyldopa 37 7.9E-01 20 2.1E-01 40 5.2E-05 39 5.2E-05
Naproxen 37 6.2E-01 30 1.8E-01 20 1.6E-01 2 3.6E-02
Nefazodone 37 4.2E-01 26 2.7E-01 24 1.8E-01 28 1.3E-01
Nitrofurantoin 37 1.0E+00 40 4.6E-05 39 4.6E-05 38 4.6E-05
Phenytoin 7 3.0E-01 37 2.5E-01 3 2.1E-01 35 1.6E-01
Simvastatin 31 4.9E-01 37 4.4E-01 34 6.1E-02 26 1.0E-02
Sulfamethoxazole/
trimethoprim
7 8.3E-01 28 1.7E-01 40 3.5E-05 39 3.5E-05
Sulfasalazine 7 6.8E-01 37 3.2E-01 40 3.2E-05 39 3.2E-05
Tolcapone* 37 6.4E-01 25 2.7E-01 3 8.7E-02 40 3.1E-05
Troglitazone* 37 4.6E-01 31 4.2E-01 1 1.1E-01 40 2.2E-05
Valproate 35 4.2E-01 38 3.1E-01 26 2.1E-01 14 5.2E-02
*These three drugs are withdrawn from the market due to the drug-induced ALF.
Topic-37 is the ALF-Topic.
Topic ID: serial number of topics in topic model.
Prob.: conditional probability of each topic to a drug.
Topic model ranks topics in accordance to their probability to each drug.
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topics between 10 and 150 (Figure 2). Then, the mean
probability value (θ) for each topic was calculated for 26
known ALF drugs. As shown in Figure 3, Topic-37 had
significantly higher probability value (0.36) to these
drugs compared to the baseline (0.02) from the rest of
topics (p < 0.01). Therefore, this topic was considered
as an ALF recognizing/predicting topic and denoted as
ALF-Topic.
The following 15 words were prevalently represented
in ALF-Topic: “case, acute, hepatic, therapy, serum, pat-
tern, week, clinical, report, jaundice, hepatocellular,
patient, typical, severe, aminotransferase“. Three of
these words (i.e., jaundice, hepatocellular, and severe)
were unique to this topic and were not simultaneously
Figure 1 Workflow of this study. The 26 known ALF drugs are from the Suzuki’s paper [12]. ALF: acute liver failure; FAERS: FDA Adverse Event
Reporting System; Hy’s law: a well-accepted rule to incriminate ALF [17].
Figure 2 Log-likelihood of the data (D) given the model (M)
with different settings of the number of topics (T).
Figure 3 Mean probability values of all 40 topics for the 26
known ALF drugs
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present in first 15 words for the other 39 topics. These
specific words might imply a clinical phenomenon likely
to indicate the potential of a drug to cause ALF. Thus,
ALF-Topic could be applied to identify other ALF-
related drugs in this model based on the probability
values of this topic to those drugs.
Application of ALF-Topic
For 12 (12/26; ~46%) known ALF drugs listed in Table
1, ALF-Topic (i.e., Topic-37) was ranked as the first
topic, and this proportion was significantly higher com-
pared to that of the other topics (p < 0.05). For five
other drugs (i.e., Benzbromarone, Halothane, Phenytoin,
Simvastatin, and Sulfasalazine), ALF-Topic was ranked
as the second, while for Ibuprofen it was in the third
place. There were no ALF drugs with ALF-Topic ranked
in the fourth place. The results suggested that a drug
with ALF-Topic ranked among its first three topics
might have a high likelihood to be associated with ALF.
This criterion (i.e., ALF-associated drugs would have
ALF-Topic ranked among their first three topics in the
model) was applied to the rest of drugs in the LiverTox
database, and a total of 127 drugs were identified.
Confirmation of drugs identified by ALF-Topic
Among the identified drugs, 77/127 (60.6%) drugs were
described in their “Outcome and management” sections
with the ALF-related terms such as “liver failure”, “hepa-
tic failure”, “liver transplantation”, “fatal/death”, or “ful-
minant hepatitis” (Additional file 1: Table S1). The
remaining 50/127 (39.4%) ALF-implicated drugs were
not mentioned to cause ALF in the LiverTox database
(Table 2). We examined the safety sections in the FDA-
approved drug labels, and found out that 13/50 (26%)
drugs were mentioned to have ALF risk in the Warnings
& Precautions, and/or Adverse reactions sections (Table
2). For another 7 drugs (7/50; 14%), there were reports
for drug-induced ALF with the established causality in
literature [12-15]. For the remaining 30 drugs, we found
that 22 (22/50; 44%) drugs had the ALF case reports in
the FAERS (Additional file 2: Table S2), which were
obtained by searching the FAERS with the Medical Dic-
tionary for Regulatory Activities (MedDRA) preferred
terms: “acute hepatic failure“ and/or “hepatic failure“.
Apart from 4 herbal medicines (i.e, Aloe Vera, Ba Jiao
Lian, Chi R Yun, and Shosaikoto/daisaikoto), which
were not recorded by the FAERS, no ALF case was
Table 2 Summary of 50 drugs implicated by ALF-Topic without apparent ALF evidence in the LiverTox database
Drug name 1st topic 2nd topic 3rd topic
Topic ID Prob. Topic ID Prob. Topic ID Prob.
Atovaquone† 37 6.2E-01 14 3.8E-01 40 5.9E-05
Buprenorphine† 22 4.1E-01 37 3.1E-01 31 2.5E-01
Clarithromycin† 37 5.3E-01 17 2.6E-01 3 1.8E-01
Diflunisal† 37 3.6E-01 38 2.6E-01 29 2.2E-01
Flecainide† 37 4.3E-01 18 2.7E-01 30 2.1E-01
Infliximab† 37 5.4E-01 14 3.6E-01 39 9.6E-02
Methimazole† 37 6.1E-01 7 3.9E-01 40 4.4E-05
Minocycline† 37 8.9E-01 35 1.1E-01 40 6.9E-05
Nabumetone† 38 4.2E-01 36 4.2E-01 37 1.5E-01
Proguanil† 37 5.8E-01 14 4.2E-01 40 4.0E-05
Salsalate† 38 6.4E-01 37 1.9E-01 30 1.7E-01
Ticlopidine† 37 4.5E-01 31 2.9E-01 7 2.5E-01
Topiramate† 35 4.9E-01 37 3.5E-01 5 1.7E-01
Chlorzoxazone* 37 6.4E-01 17 2.2E-01 20 1.0E-01
Cocaine* 29 4.7E-01 37 2.4E-01 23 1.7E-01
Chlorpromazine* 13 7.0E-01 21 1.9E-01 37 1.1E-01
Greater celandine* 37 8.2E-01 20 9.8E-02 34 5.9E-02
Hydralazine* 37 6.7E-01 17 3.0E-01 35 3.4E-02
Jin bu huan* 37 5.7E-01 27 2.6E-01 14 1.7E-01
Shouwupian* 37 9.8E-01 27 2.1E-02 40 5.2E-05
Colchicine‡§ 33 4.0E-01 37 2.5E-01 9 1.9E-01
Fenofibrate‡§ 37 8.7E-01 33 1.3E-01 40 2.7E-05
Mebendazole‡§ 5 4.6E-01 2 2.5E-01 37 2.3E-01
Metformin‡§ 37 6.2E-01 10 3.5E-01 32 2.8E-02
Nifedipine‡§ 37 5.9E-01 14 2.2E-01 21 1.7E-01
Verapamil‡§ 37 5.9E-01 21 3.6E-01 9 5.1E-02
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reported for the remaining 4 drugs (i.e., Clofibrate,
Methocarbamol, Pentamidine, and Reserpine). In sum-
mary, among 127 identified drugs, evidence supporting
risk of ALF was found for 119 drugs (119/127; 93.7%).
Discussion
In this proof-of-concept study, topic modeling was
demonstrated to be a promising approach to leverage
information from drug safety databases comprised of tex-
tual data. As a case study, LiverTox database was
explored by topic modeling to discover the hidden pat-
tern for the identification of drugs potentially causing
ALF. We deliberately chose to analyze the LiverTox
“Hepatotoxicity” section alone so the findings could be
verified by other sections in the LiverTox to demonstrate
the potential utility of topic model in the field of drug
safety. Specifically, first, ALF-Topic from the “Hepato-
toxicity” sections of the drug documents was discovered,
which was interpreted by the prevalence of three specific
words (i.e., jaundice, hepatocellular, and severe). Then,
this topic was applied to identify ALF-related drugs in
the LiverTox database. Thereafter, evidence supporting
risk of ALF for those identified drugs was found from the
“Outcome and management” sections of the LiverTox or
found from other public databases if not available from
the LiverTox.
ALF-Topic was confirmed to be relevant to the well-
known Hy’s law [16,17], which defines that the observed
drug-induced hepatocellular liver injury pattern together
with jaundice has a poor prognosis with 10~50% fatality
of ALF. The predictive power of Hy’s law has been veri-
fied by the analysis of extensive studies in Spain and
Sweden [18,19], and it has been recommended by the
FDA for assessing the potential of a drug to cause
severe DILI [20]. In this study, ALF-Topic identified
127 drugs in the LiverTox database, and approximately
60% (77/127) of these drugs were implicated to cause
ALF in their “Outcome and management” sections. For
Table 2 Summary of 50 drugs implicated by ALF-Topic without apparent ALF evidence in the LiverTox database
(Continued)
Acebutolol‡ 37 5.4E-01 5 4.6E-01 40 3.6E-05
Adefovir‡ 26 5.9E-01 37 3.1E-01 30 9.6E-02
Alfuzosin‡ 21 6.0E-01 37 2.2E-01 30 1.8E-01
Ceftriaxone‡ 37 5.3E-01 33 3.3E-01 7 8.0E-02
Gold salts‡ 37 7.0E-01 39 1.9E-01 4 1.1E-01
Linezolid‡ 6 3.9E-01 36 2.6E-01 37 2.0E-01
Montelukast‡ 31 4.3E-01 37 3.4E-01 5 2.1E-01
Olanzapine‡ 37 5.9E-01 13 1.8E-01 19 1.7E-01
Orphenadrine‡ 29 5.8E-01 37 3.7E-01 11 5.2E-02
Oxacillin‡ 37 5.8E-01 4 3.7E-01 12 4.5E-02
Phenelzine‡ 31 6.2E-01 37 3.6E-01 1 1.9E-02
Risperidone‡ 37 6.4E-01 13 3.2E-01 18 2.9E-02
Sotalol‡ 32 4.7E-01 37 4.3E-01 7 1.0E-01
Thioridazine‡ 13 8.4E-01 37 1.6E-01 40 4.0E-05
Ticarcillin/clavulanate‡ 37 4.5E-01 4 3.2E-01 3 2.3E-01
Trisalicylate‡ 38 5.4E-01 37 4.6E-01 40 4.1E-05
Clofibrate 37 4.0E-01 31 3.4E-01 33 2.6E-01
Methocarbamol 37 3.5E-01 25 3.3E-01 38 2.9E-01
Pentamidine 37 7.7E-01 29 2.3E-01 40 5.7E-05
Reserpine 37 5.3E-01 36 3.2E-01 9 9.3E-02
Aloe Vera 37 6.1E-01 9 2.8E-01 36 1.1E-01
Ba Jiao Lian 25 5.9E-01 37 4.1E-01 40 6.4E-05
Chi R Yun 25 3.2E-01 37 2.7E-01 11 2.4E-01
Shosaikoto/daisaikoto 37 7.6E-01 23 2.4E-01 40 3.8E-05
†26% (13/50) drugs confirmed by safety concerns about ALF in the FDA-approved drug labels.
*14% (7/50) drugs confirmed by the literature with justified ALF causality.
‡44% (22/50) drugs confirmed by ALF case reports in the FAERS.
§These 6 drugs were predicted as ALF positive drugs by the in vitro experiment.
Topic-37 is the ALF-Topic.
Topic ID: serial number of topics in topic model.
Prob.: conditional probability of each topic to a drug.
Topic model ranks topics in accordance to their probability to each drug.
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those unspecified drugs, supporting evidence was found
for 20 drugs in safety sections of their FDA-approved
drug labels or in the literature with established ALF
causality. ALF case reports were identified in the
FAERS for the other 22 drugs, among which, 6 drugs
were predicted as ALF positive drugs by an in vitro
experiments. While the in vitro data might not directly
indicate the ALF potential in humans, it was demon-
strated that these 6 drugs were much closer to the ALF
positive control drugs when they were tested by in vitro
experiment. Evidence of ALF from the FAERS should
be interpreted cautiously, because the causality may not
be fully established. For example, although ALF cases of
Phenelzine were reported in the FAERS, it was empha-
sized that Phenelzine might not be the suspect drug [21].
In addition to the overestimated risk, the FAERS only
receives reports from the United States. For example,
Ethionamide was not reported ALF in the FAERS despite
being known to cause ALF in the United Kingdom [22].
For 127 identified drugs, evidence supporting risk of
ALF was found for 119 drugs. The result strongly sug-
gests that not only the specific wording but also their
probabilistic/statistic relationship in the hidden structure
of textual documents were crucial to incriminate drugs
for ALF. It is worthwhile to point out that it is beyond
the scope of this excise to ask ALF-Topic to identify all
ALF-related drugs because ALF mechanisms are com-
plex and the selected 26 known ALF drugs for deter-
mining ALF-Topic do not necessary represent the entire
landscape of ALF. For example, hepatocellular liver
injury pattern is not observed for Efavirenz and Dicloxa-
cillin, which have the potential to cause ALF [12]. Ator-
vastatin and Ethambutol, known as ALF drugs [12], are
not mentioned to cause either jaundice or hepatocellular
liver injury in the LiverTox database.
Conclusions
We explored the LiverTox database using topic model-
ing, and discovered the hidden knowledge to identify
drugs with potential to cause ALF. Our proof-of-concept
study demonstrates the applicability of topic modeling
to leverage information within the textual drug safety
databases, which will provide new opportunities for
drug safety assessment.
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